Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029911 | 0.87 | HTR1A (0.43) | L3MBTL1KMT2ATDP1SMN1; SMN2TSHR | |
| SCHEMBL26551000 | 0.85 | L3MBTL1 (0.48) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL23227287 | 0.85 | ATM (0.42) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL792228 | 0.84 | KMT2A (0.48) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL10400020 | 0.83 | KMT2A (0.42) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL10399682 | 0.83 | KMT2A (0.42) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL24030143 | 0.80 | L3MBTL1 (0.41) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL30098996 | 0.79 | HPGD (0.40) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL4630504 | 0.77 | ATM (0.50) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL30403309 | 0.77 | KDM4E (0.42) | ATMKMT2AMEN1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| WO-2021227440-A1 | A CLASS OF ARYL GLUCOSIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海喆邺生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331761-A1 | Aryl Glucoside Derivative, Preparation Method Therefor And Application Thereof | SLC5A1, SLC5A2, SLC10A1 | ATM 4395/4885L3MBTL1 3392/4885KMT2A 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.